This is a working overview of AEDG, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Linear tetrapeptide, also written AEDG |
| Molecular mass | About 390.35 g/mol | Value calculated from the sequence |
| Appearance | White to off-white powder | Lyophilised material forms a loose cake |
| Solubility | Freely soluble in water | Also dissolves in isotonic saline |
| Storage | -20 °C, desiccated | Aliquot solutions to avoid freeze–thaw cycling |
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Some individuals with CAIS may choose to retain their gonads. If this is the case, annual imaging of the gonads via MRI or ultrasound is recommended in order to monitor for signs of malignancy. Diagnostic laparoscopy and biopsy are also to be considered if imaging is ambiguous. A study in 2012 claimed that adult women with CAIS are increasingly likely to keep their gonads due to perceived benefits. A retrospective study which includes postpubertal CAIS individuals seen at a single UK DSD center shows that there has been a temporal shift away from gonadectomy. 76.5% CAIS individuals between 2020 and 2025 elected to retain their gonads in this study. Endogenous hormone profiles show very specific features that influence bone health, hormonal replacement therapy may improve bone mineral density, but it does not normalize it. For individuals with CAIS who wish to keep their gonads, a biannual screening program is proposed. It may be possible to avoid gonadectomy throughout the patient's life with regular imaging and routine monitoring to ensure the gonads are healthy. It is emphasized that not all imaging abnormalities are indicative of malignancy. Some activists consider that cancer risk is used to legitimate surgical and hormonal intervention because intersex bodies were positioned as inherently sick and in need of modification. Research also suggest that timely intervention to reduce genotoxicity such as DNA damage, inflammation and imbalanced autophagy may promote germ cells specification and decrease the risk of germ cells tumor.
=== Detectors === HPLC detectors fall into two main categories: universal or selective. Universal detectors typically measure a bulk property (e.g., refractive index) by measuring a difference of a physical property between the mobile phase and mobile phase with solute while selective detectors measure a solute property (e.g., UV-Vis absorbance) by simply responding to the physical or chemical property of the solute. HPLC most commonly uses a UV-Vis absorbance detector; however, a wide range of other chromatography detectors can be used. A universal detector that complements UV-Vis absorbance detection is the charged aerosol detector (CAD). A kind of commonly utilized detector includes refractive index detectors, which provide readings by measuring the changes in the refractive index of the eluant as it moves through the flow cell. In certain cases, it is possible to use multiple detectors, for example LCMS normally combines UV-Vis with a mass spectrometer. When used with an electrochemical detector (ECD) the HPLC-ECD selectively detects neurotransmitters such as: norepinephrine, dopamine, serotonin, glutamate, GABA, acetylcholine and others in neurochemical analysis research applications. The HPLC-ECD detects neurotransmitters to the femtomolar range. Other methods to detect neurotransmitters include liquid chromatography-mass spectrometry, ELISA, or radioimmunoassays.
==== Functional selectivity ==== An animal study found that two different kinds of androgen response elements could differentially respond to testosterone and DHT upon activation of the AR. Whether this is involved in the differences in the ratios of anabolic-to-myotrophic effect of different AAS is unknown however.
Nanospray desorption electrospray ionization (nano-DESI) is an ambient pressure ionization technique used in mass spectrometry (MS) for chemical analysis of organic molecules. In this technique, analytes are desorbed into a liquid bridge formed between two capillaries and the sampling surface. Unlike desorption electrospray ionization (DESI), from which nano-DESI is derived, nano-DESI makes use of a secondary capillary, which improves the sampling efficiency.
== Legislative and regulatory matters == Traceability of food is legally required in the European Union (Regulation 178/2002) with dedicated initiatives in EU countries and the UK and Northern Ireland. In the EU, under the renewed Sustainable Product Policy Initiative, the inclusion of a Digital Product Passport has been proposed. The EU sustainable product policy was renewed in function of the European Green Deal and the new Circular Economy Action Plan. and revises the Ecodesign Directive. As such, similarly to material passports, it intents to assist the circular economy. In the United States, various government agencies have oversight or regulatory control over different aspects of fresh fruit and produce production, processing and distribution. These include the U.S. Department of Agriculture, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control. Some groups have pushed for a single food-safety agency, on-farm improvements and improved reporting and surveillance of foodborne illness outbreaks. The draft Food Safety Enhancement Act of 2009 was introduced May 27, 2009, in the U.S. House of Representatives. It would expand FDA authority, require registration of food manufacturers and processors, regulate crop cultivation and harvesting and other measures. After committee hearings and extensive amendment, the bill (HR2749) passed the House on July 30, 2009. HR2749 does not specifically endorse the PTI, or prescribe a traceability method or methodology, but instead Section 107 calls for regulations establishing a tracing system that includes:
Sources: en.wikipedia.org
=== Structure === The main structure of the blue cheese comes from the aggregation of the casein. In milk, casein does not aggregate because of the outer layer of the particle, called the "hairy layer." The hairy layer consists of κ-casein, which are strings of polypeptides that extend outward from the center of the casein micelle. The entanglement of the hairy layer between casein micelles decreases the entropy of the system because it constrains the micelles, preventing them from spreading out. Curds form, however, due to the function that the enzyme, rennet, plays in removing the hairy layer in the casein micelle. Rennet is an enzyme that cleaves the κ-casein off the casein micelle, thus removing the strain that occurs when the hairy layer entangles. The casein micelles are then able to aggregate together when they collide with each other, forming the curds that can then be made into blue cheese.
Other physiological factors include neurotransmitters and hormones that impact positive feelings, such as endorphin, dopamine, serotonin, oxytocin, and cortisol. Biologists are also interested in the evolutionary origins of subjective well-being. This perspective understands happiness and unhappiness not as ends but as tools to regulate behavior, guiding it toward fitness-enhancing outcomes. It holds that subjective well-being is a product of natural selection: its underlying hereditary traits are passed on to future generations if they promote survival and reproduction. In neuroscience, researchers try to uncover the neural correlates of well-being using neuroimaging techniques, such as functional magnetic resonance imaging. The problem of well-being plays a central role in medicine since medical interventions typically aim to restore, secure, and enhance patient well-being. Considerations of well-being also affect the treatment of incurable diseases, like Parkinson's disease. In such cases, therapies aim to minimize negative effects, helping patients lead productive and fulfilling lives despite their illness. However, well-being is not the only consideration governing medical interventions, and the commitment to patient autonomy is another core principle. This can lead to conflicts when patients act against their self-interest and reject treatments that would improve their well-being.
== AFL career == Lovett-Murray was initially rookie listed by Collingwood, playing for the Williamstown Seagulls in the Victorian Football League. After switching to the Bendigo Bombers, he was rookie listed by Essendon in the 2003 Rookie Draft. Lovett-Murray was promoted to the senior list early in the 2004 season and played 20 games. He spent the 2005 season on the rookie list again, he was promoted again that season and stayed on the senior list since then. In 2006, Lovett-Murray copped a three-game suspension from the AFL Tribunal for intentionally striking Fremantle midfielder Matthew Carr in the Bombers' round fourteen loss to the Dockers at Subiaco Oval. This was one of many lowlights for the club, which finished 15th at the end of the season with just three wins and one draw from 22 matches played. Lovett-Murray, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in December 2016; as a result, he served approximately fifteen months of his suspension and missed the entire 2016 season, when he had intended to play and coach for Rumbalara Football Club.
==== Claims that 'whoonga' or 'nyaope' is made from anti-retrovirals, rat poison, etc. ==== Sensationalist media reports have often claimed that ‘whoonga’ or ‘nyaope’ is a uniquely South African drug containing ingredients such as rat poison, anti-retroviral medication, and materials gleaned from the cathode tubes in stolen flat screen televisions. However scientific laboratory studies have shown these claims to be urban legends, and that 'whoonga' and 'nyapoe' are in fact simply heroin and do not contain the aforementioned adulterants. According to researcher Jesse Copelyn it "has been shown "that media accounts that frame nyaope as a new and exotic drug are misleading" and "have obscured the fact that South Africa simply has a major heroin crisis".
Sources: en.wikipedia.org
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.
AEDG is the one-letter code for the four amino acids alanine, glutamate, aspartate and glycine in that order. The same molecule is written in three-letter form as Ala-Glu-Asp-Gly.
Identity is normally confirmed by mass spectrometry against the calculated mass of roughly 390.35 g/mol. Purity is then estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.